BRAINTREE LABORATORIES, INC. IN-LICENSES GLOBAL RIGHTS TO ONCOLOGY DRUG PLATFORM
Inc. today announced that it has in-licensed the global rights to develop and
commercialize BLI-600, a patent protected compound that has shown significant
promise as a chemoprevention agent, from INRA Transfert (IT), a subsidiary of
National Institute for Agricultural Research (INRA), Paris, France. Under the
terms of the agreement, Braintree Laboratories is responsible for the clinical
development and worldwide registration of the compound for chemoprevention and/or
treatment of colorectal cancer.